Klein protocol, age-tiered maximum doses, CYP1A2 maturation, and fractional toxicity coupling
Clinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals. It does not replace clinical judgment. Always verify dosing against current guidelines, institutional protocols, and patient-specific factors before administration.
Tumescent lidocaine dosing is stratified into three age tiers based on CYP1A2 enzyme maturity and pharmacokinetic data from the Klein and Blunt studies.
| Age Tier | Age Range | Max Dose (mg/kg) | Absolute Max (mg) | Source |
|---|---|---|---|---|
| Not Eligible | < 6 months | Contraindicated — immature CYP1A2 (approx. 1/3 adult clearance) | — | |
| Pediatric | 6 months – 11 years | 7 mg/kg | — | Blunt 2003 |
| Adolescent & Adult | 12+ years | 28 – 35 mg/kg | 3,500 mg | Klein 2016 |
Under 6 Months — Not Eligible. Infants under 6 months of age have profoundly immature CYP1A2 activity (approximately one-third of adult clearance). Tumescent lidocaine is contraindicated in this age group. Standard lidocaine with age-adjusted dose reductions should be used instead.
Dose range convention: For the 12+ age tier, the lower bound (28 mg/kg) is the conservative default used for fractional toxicity calculations. Doses between 28 and 35 mg/kg trigger a soft warning. The absolute maximum of 3,500 mg applies regardless of patient weight.
Tumescent lidocaine dosing permits substantially higher mg/kg doses than standard lidocaine infiltration. This is not because the drug is different — it is the same molecule — but because the technique fundamentally alters the pharmacokinetics of absorption.
The tumescent technique involves infiltrating large volumes of very dilute lidocaine (0.05–0.1%) in normal saline with epinephrine into the subcutaneous tissue. This creates a fluid-distended ("tumescent") tissue plane that provides:
Key pharmacokinetic insight: The 12–14 hour delay to peak plasma levels is the primary pharmacologic justification for higher mg/kg dosing. Because lidocaine is metabolized with a half-life of approximately 1.6 hours, systemic accumulation is limited even at high total doses when absorption is this slow.
Lidocaine is metabolized primarily by the hepatic enzyme CYP1A2. The maturation timeline of this enzyme is the basis for the tumescent age tiers:
| Age | CYP1A2 Status | Clinical Implication |
|---|---|---|
| < 6 months | Approx. 1/3 adult activity | Tumescent NOT eligible — severely impaired lidocaine clearance |
| 6 months – 7 years | Maturing, below adult levels | Reduced 7 mg/kg cap; conservative dosing |
| 7–8 years | Reaches adult activity | Enzyme maturity milestone |
| 12+ years | Full adult activity | Full tumescent dosing (28–35 mg/kg) |
Why 12 years, not 8? Although CYP1A2 reaches adult activity around 7–8 years, the adult tumescent dosing threshold is set at 12 years. The pediatric 7 mg/kg cap (6 months – 11 years) from the Blunt 2003 study provides a conservative buffer during the transition period.
When multiple local anesthetics are administered to the same patient, their toxicities are additive. Fractional toxicity (FT) tracks the cumulative systemic burden as a fraction of each agent's maximum dose. Tumescent lidocaine receives special treatment in this calculation.
A tumescent dose always counts against its own budget in full. Its coupling to other agents is attenuated because tumescent lidocaine peaks at 12–14 hours (vs. 30–60 minutes for standard agents), so peak systemic burden rarely overlaps with other local anesthetics given in the same session. MaxLocal charges the tumescent dose at 100% of its own maximum and applies a 50% coupling factor to fractional toxicity contributed by other agents:
| Contribution | Coupling Factor | Rationale |
|---|---|---|
| Tumescent dose toward its own max | 100% | You cannot give a maximal tumescent dose and still have tumescent capacity remaining |
| Other agents toward tumescent remaining | 50% | Peak plasma 12–14 hours — minimal overlap, but same drug / same CYP1A2 pathway; conservative hedge |
Standard agents: remainingMg = floor((1.0 - currentFT) * maxMg)
Tumescent lidocaine: remainingMg = floor(max(0, tumescentMaxMg - givenTumescentMg - ftOther * 0.50 * tumescentMaxMg)), where ftOther is fractional toxicity from non-tumescent agents.
The TUMESCENT_FT_ATTENUATION = 0.50 constant applies only to ftOther; the tumescent dose's own milligrams are subtracted directly.
The contrast between tumescent and standard lidocaine dosing illustrates how technique-dependent pharmacokinetics alter safe dosing limits for the same drug molecule.
| Parameter | Standard Lidocaine | Tumescent Lidocaine |
|---|---|---|
| Max dose (mg/kg) | 4.5 – 5 mg/kg (without epi) 7 mg/kg (with epi) | 28 – 35 mg/kg |
| Absolute max (mg) | 300 mg (without epi) 500 mg (with epi) | 3,500 mg |
| Concentration | 0.5% – 2% | 0.05% – 0.1% |
| Peak plasma | 30 – 60 minutes | 12 – 14 hours |
| Epinephrine | Optional (separate formulation) | Included in tumescent solution |
| FT coupling (to other agents) | 100% | 50% (own dose 100%) |
| Under 6 months | Eligible (with age-adjusted dose reduction) | Not eligible |
The Klein tumescent lidocaine protocol uses very dilute lidocaine (0.05–0.1%) mixed with epinephrine in large volumes of normal saline, infiltrated subcutaneously. Originally developed for liposuction anesthesia, Klein demonstrated that this technique permits doses of 28–35 mg/kg (absolute cap 3,500 mg) due to the delayed systemic absorption profile.
Tumescent solutions use lidocaine concentrations of 0.05% to 0.1% (0.5 to 1 mg/mL). This is far more dilute than standard lidocaine infiltration concentrations (0.5–2%, or 5–20 mg/mL). The high dilution is essential to the pharmacokinetic profile that permits higher total doses.
Epinephrine is a standard component of the tumescent solution (typically 1:1,000,000 concentration). It serves two purposes: local vasoconstriction to slow systemic absorption, and hemostasis in the surgical field. Because epinephrine is already included in the tumescent formulation, the dosing limits already account for its vasoconstrictive effect — there is no separate "with epi" tier for tumescent lidocaine.
The pediatric tumescent dose of 7 mg/kg (Blunt 2003) was established in a burns population aged 6 months to 11 years. This matches the standard lidocaine-with-epinephrine dose rather than the higher adult tumescent dose. The conservative approach reflects both limited pediatric pharmacokinetic data for tumescent lidocaine and the ongoing CYP1A2 maturation in this age group.
For patients aged 12 years and older, the maximum tumescent lidocaine dose is 28–35 mg/kg with an absolute cap of 3,500 mg (Klein 2016). Children aged 6 months to 11 years may receive up to 7 mg/kg (Blunt 2003). Tumescent lidocaine is contraindicated in infants under 6 months due to immature CYP1A2 metabolism (approximately one-third of adult clearance).
Tumescent lidocaine uses large volumes of very dilute lidocaine (0.05–0.1%) in saline with epinephrine. The subcutaneous fat acts as a slow-release reservoir, delaying peak plasma levels to 12–14 hours compared to 30–60 minutes for standard lidocaine infiltration. This temporal separation, combined with local vasoconstriction from epinephrine in the tumescent solution, justifies the substantially higher mg/kg dosing (28–35 mg/kg vs. 4.5–5 mg/kg standard).
Tumescent lidocaine can be used in children aged 6 months and older at a reduced dose of 7 mg/kg (Blunt 2003). It is contraindicated in infants under 6 months because CYP1A2, the primary enzyme metabolizing lidocaine, is profoundly immature at that age — approximately one-third of adult activity. CYP1A2 does not reach full maturity until 7–8 years of age.
The Klein tumescent lidocaine protocol uses very dilute lidocaine (0.05–0.1%) mixed with epinephrine in large volumes of normal saline, infiltrated subcutaneously. Klein demonstrated that this technique permits lidocaine doses of 28–35 mg/kg (absolute cap 3,500 mg) because the dilute subcutaneous depot results in extremely slow systemic absorption, with peak plasma levels delayed to 12–14 hours. The protocol was originally developed for liposuction anesthesia and has since been applied to other procedures requiring large-area anesthesia.
Weight-based dosing, age-tiered tumescent limits, fractional toxicity coupling with 50% cross-agent attenuation, and instant LAST protocol access — all offline.
Get MaxLocal on Google PlayClinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Always verify information against current guidelines and institutional protocols before clinical use.